|
Evaluating Cardiac Safety of Trastuzumab in Iraqi Women with Breast Cancer
|
|
| Author:
|
BAHIR RAZZAQ, SABA RABEE ABDUL AZIZ, FATIMA THABET MOHSEN
|
| Abstract:
|
Trastuzumab,an immunotherapy which indicated for overexpression of human epidermal growth factor receptor 2
(HER2) in breast cancer disorders, with a risk of cardiac toxicity. This study was design to present the incidence of
cardiac toxicity and its associated risk factors for breast cancer women receiving trastuzumab.This retrospective
observational study enrolled 50 women with positive HER2 breast cancer who received trastuzumab in theBaghdad
Oncology Centers, from August 2017 to March 2018. The incidence of cardiotoxicity and associated risk factors
during treatment withtrastuzumab was evaluated. From 50 patient,18 (36%) exhibited cardiac complications, 12 % of
them reduced their LVEF below 50%, 30% reduced their LVEF >10 points below their baseline, while 6% reduced
their LVEF >15 points below their baseline.Of those 18, 8 patients (44.4%) stopping treatment because of drop in
LVEF. In 7 of those patients, trastuzumab re-administered after normalization of EF values.Treatment course of
trastuzumab was completed in 98% (49 patients), while2% (1 patient) required trastuzumab discontinuation
definitively, as LVEF not recovered completely. Risk factors for cardiac toxicity included: patients elder than 65 years
(p < 0.046), patients with low baseline LVEF (p < 0.027), those with concomitant and previous radiotherapy to the left
side of the chest (p < 0.039), and those with elevated troponin levels at baseline (p < 0.034). In this study,
trastuzumab-related cardiotoxicitywas comparable with that of literature data.This toxicityrepresented by
asymptomatic LVEFreduction and less frequently symptomaticcardiac dysfunction. Most cases were transient and
reversible.
|
| Keyword:
|
breast cancer; trastuzumab;cardiotoxicity;risk factors.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2019.11.01.065
|
| Download:
|
Request For Article
|
|
|